Adjuvants With Intrathecal Bupivacaine for Postoperative Analgesia
Postoperative Pain
About this trial
This is an interventional prevention trial for Postoperative Pain
Eligibility Criteria
Inclusion Criteria: Adult patients aged 18-60 years. Gender: Both males and females. Scheduled patients for High tibial osteotomy under spinal anesthesia. American Society of Anesthesiologists (ASA) physical status: I and II Exclusion Criteria: Patient refusal Allergy to the studied drugs. Patients with contraindications to spinal anesthesia. Patients with advanced decompensated cardiac, respiratory,renal or hepatic diseases Coagulopathy or thrombocytopenia CNS diseases as epilepsy, stroke or psychiatric illness.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Group M (midazolam group)
Group D(dexmedetomidine group)
Group C(control group)
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 1 mg midazolam (8 units of 5 mg/mL preservative-free midazolam loaded in a 40 unit insulin syringe).
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 5 mcg dexmedetomidine (2 units of 100 mcg/mL preservative-free dexmedetomidine loaded in a 40 unit insulin syringe).
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 0.5 mL of 0.9% saline .